Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

LYMPHOMA

A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Consort diagram and EFS/OS.

References

  1. 1.

    Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–43.

    Google Scholar 

  2. 2.

    Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/=15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30:387–93.

    Google Scholar 

  3. 3.

    Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.

    Google Scholar 

  4. 4.

    Ehrhardt MJ, Chen Y, Sandlund JT, Bluhm EC, Hayashi RJ, Becktell K, et al. Late health outcomes after contemporary lymphome Malin de Burkitt therapy for mature b-cell non-hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol. 2019;37:2556–70.

    Google Scholar 

  5. 5.

    Teepen JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, van den Heuvel-Eibrink MM, van der Pal HJ, et al. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy. J Clin Oncol. 2017;35:2288–98.

    Google Scholar 

  6. 6.

    Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–36.

    Google Scholar 

  7. 7.

    Banerjee P, Rossi MG, Anghelescu DL, Liu W, Breazeale AM, Reddick WE, et al. Association between anesthesia exposure and neurocognitive and neuroimaging outcomes in long-term survivors of childhood acute lymphoblastic leukemia. JAMA Oncol. 2019.

  8. 8.

    Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia. 2013;27:1174–7.

    Google Scholar 

  9. 9.

    Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. Br J Haematol. 2014;167:394–401.

    Google Scholar 

  10. 10.

    Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004;22:3916–21.

    Google Scholar 

  11. 11.

    Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, et al. Revised international pediatric non-hodgkin lymphoma staging system. J Clin Oncol. 2015;33:2112–8.

    Google Scholar 

  12. 12.

    Sandlund JT, Guillerman RP, Perkins SL, Pinkerton CR, Rosolen A, Patte C, et al. International pediatric non-hodgkin lymphoma response criteria. J Clin Oncol. 2015;33:2106–11.

    Google Scholar 

  13. 13.

    Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children’s Oncology Group report. Br J Haematol. 2013;162:678–83.

    Google Scholar 

  14. 14.

    Minard-Colin V, Auperin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for high-risk, mature B-cell non-Hodgkin’s lymphoma in children. N Engl J Med. 2020;382:2207–19.

    Google Scholar 

  15. 15.

    Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

    Google Scholar 

Download references

Acknowledgements

This manuscript is supported by a grant from Pediatric Cancer Research Foundation (PCRF), Pediatric Cancer Foundation (PCF), and Leadiant Biosciences, Inc. (MC). The authors would like to thank the patients and their families who participated in the trial. We would also like to thank Virginia Davenport, RN, and Erin Morris, RN for their editorial assistance and the Data Safety Monitoring Committee: Oussama Abla, MD, Michelle Hermiston, MD, Sharon Bergeron, RN, and Joseph Laver, MD.

Author information

Affiliations

Authors

Contributions

SG and MSC conceived and designed the study; SG, LH, MB, QS, YC, and MC collected the data and SG, MB, QS, YC, and MC analyzed and interpreted the data; and SG, QS, LH, and MC wrote the manuscript. All authors reviewed, revised and approved the final draft of the manuscript prior to submission.

Corresponding author

Correspondence to Mitchell Cairo.

Ethics declarations

Conflict of interest

MC is on the advisory board for Jazz Pharmaceuticals and Nektar Therapeutics and the speaker bureau for Jazz Pharmaceuticals, Servier Pharmaceuticals, Sanofi Pharmaceuticals and Amgen, Inc. SG is on the speaker bureau for Jazz Pharmaceuticals. All other authors declare no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Presented in part at the Sixth International Symposium on Childhood, Adolescent and Young Adult non-Hodgkin lymphoma, 2018, Rotterdam, Netherlands.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Goldman, S., Barth, M., Shiramizu, B. et al. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia (2021). https://doi.org/10.1038/s41375-021-01256-8

Download citation

Search

Quick links